U.S. patent application number 13/521326 was filed with the patent office on 2013-01-24 for diagnostic for cancer.
This patent application is currently assigned to THE UNIVERSITY OF TOKYO. The applicant listed for this patent is Tetsuo Nagano, Masayo Sakabe, Yasuteru Urano. Invention is credited to Tetsuo Nagano, Masayo Sakabe, Yasuteru Urano.
Application Number | 20130023675 13/521326 |
Document ID | / |
Family ID | 44304274 |
Filed Date | 2013-01-24 |
United States Patent
Application |
20130023675 |
Kind Code |
A1 |
Urano; Yasuteru ; et
al. |
January 24, 2013 |
DIAGNOSTIC FOR CANCER
Abstract
An agent for diagnosing cancer comprising, as an active
ingredient, a compound represented by the following formula (I)
(R.sup.1 represents hydrogen atom, or a substituent; R.sup.2 to
R.sup.7 represent hydrogen atom, hydroxyl group, an alkyl group, or
a halogen atom; R.sup.8 and R.sup.9 represent hydrogen atom, or an
alkyl group; and X represents a C.sub.1-C.sub.3 alkylene group),
which specifically emits fluorescence in a cancerous tissue within
a short time when applied to a part in which presence of a
cancerous tissue is suspected. ##STR00001##
Inventors: |
Urano; Yasuteru; (Kanagawa,
JP) ; Nagano; Tetsuo; (Tokyo, JP) ; Sakabe;
Masayo; (Kanagawa, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Urano; Yasuteru
Nagano; Tetsuo
Sakabe; Masayo |
Kanagawa
Tokyo
Kanagawa |
|
JP
JP
JP |
|
|
Assignee: |
THE UNIVERSITY OF TOKYO
Tokyo
JP
|
Family ID: |
44304274 |
Appl. No.: |
13/521326 |
Filed: |
January 12, 2011 |
PCT Filed: |
January 12, 2011 |
PCT NO: |
PCT/JP2011/050299 |
371 Date: |
October 9, 2012 |
Current U.S.
Class: |
549/344 |
Current CPC
Class: |
C07D 493/10 20130101;
A61K 31/352 20130101; A61K 49/0041 20130101; A61K 49/0043
20130101 |
Class at
Publication: |
549/344 |
International
Class: |
C07D 493/10 20060101
C07D493/10 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 13, 2010 |
JP |
2010-004797 |
Claims
1. An agent for diagnosing cancer comprising a compound represented
by the following formula (I): ##STR00005## wherein R.sup.1
represents a hydrogen atom, or the same or different one to four
substituents binding to the benzene ring; R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, and R.sup.7 independently represent a
hydrogen atom, a hydroxyl group, an alkyl group, or a halogen atom;
R.sup.8 and R.sup.9 independently represent a hydrogen atom, or an
alkyl group; and X represents a C.sub.1-C.sub.3 alkylene group, or
a salt thereof as an active ingredient.
2. The agent for diagnosing cancer according to claim 1, wherein
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7,
R.sup.8, and R.sup.9 are hydrogen atoms, and X is a methylene
group.
3. The agent for diagnosing cancer according to claim 1, which is
used for a surgical treatment of a cancer or a diagnosis for a
cancer.
4. The agent for diagnosing cancer according to claim 3, wherein
the surgical treatment of a cancer or the diagnosis for a cancer is
an open surgery, an endoscopic surgery, or endoscopy.
5. The agent for diagnosing cancer according to claim 4, which is
used for quick diagnosis during surgery.
Description
TECHNICAL FIELD
[0001] The present invention relates to an agent for diagnosing
cancer. More specifically, the present invention relates to an
agent for diagnosing cancer that specifically emits fluorescence in
a cancerous tissue within a short time when applied to a part in
which presence of a cancerous tissue is suspected.
BACKGROUND ART
[0002] Imaging diagnosis techniques such as those based on PET or
MRI have been widely used as methods for diagnosing cancers in
recent years. However, by means of these techniques, it is
difficult to find microcarcinomas not larger than 1 cm. Moreover,
these techniques also have problems that very large scale
instruments are required for imaging, and they are not suitable as
diagnostic methods for identifying a cancerous lesion to be excised
by a surgeon during surgery, endoscopy, or the like.
[0003] A cancer imaging method utilizing a probe complex consisting
of a combination of an antibody against a cancer and a pH-sensitive
fluorescent probe has recently been reported (Nat. Med., 15, pp.
104-109, 2009). This method has a characteristic feature in that
specific imaging of a cancerous tissue with fluorescence is
achievable. However, this method has problems that sensitivity of
the probe complex used in this method is insufficient, and that a
time of 1 hour or longer is required before a cancerous lesion
becomes detectable after the administration of the probe. From
these reasons, the method has not yet been practically used as a
method for prompt diagnosis of a cancerous tissue during surgery or
the like.
[0004] As fluorescent probes utilizing a xanthene structure,
fluorescent probes for measurement of protease having superior
quick responsiveness and quantiflability have been developed, and
as a fluorescent probe that specifically reacts with
.gamma.-glutamyltransferase (GGT) to give intense fluorescence
within a short time, .gamma.-Glu-RhoHM has also been reported
(Masayo Sakabe, "Development of novel fluorescent probes for enzyme
activity detection utilizing ring opening for the basis of
fluorescence control", Master's thesis in Graduate School of
Pharmaceutical Sciences, The University of Tokyo, presented in the
Master's thesis presentation meeting on Mar. 5, 2009, Abstract is
readable in The Library of Faculty of Pharmaceutical Sciences, The
University of Tokyo). However, use of this fluorescent probe for
cancer diagnosis has not yet been reported.
[0005] In addition, it has been reported that promotion of
expression of .gamma.-glutamyltransferase is observed in cancer
cells, and this expression promotion relates to drug resistance
(Biochemical Pharmacology, 71, pp. 231-238, 2006). However, any
diagnostic method for identifying a cancer cell or a cancerous
tissue with high accuracy by detecting .gamma.-glutamyltransferase
has not been reported so far.
PRIOR ART REFERENCES
Non-Patent Documents
[0006] Non-patent document 1: Biochemical Pharmacology, 71, pp
231-238, 2006 [0007] Non-patent document 2: Nat. Med., 15, pp.
104-109, 2009 [0008] Non-patent document 3: Masayo Sakabe, Master's
thesis in Graduate School of Pharmaceutical Sciences, The
University of Tokyo, presentation in the Master's thesis
presentation meeting on Mar. 5, 2009, and Abstracts of Master's
theses readable in The Library of Faculty of Pharmaceutical
Sciences, The University of Tokyo
SUMMARY OF THE INVENTION
Object to be Achieved by the Invention
[0009] An object of the present invention is to provide an agent
for diagnosing cancer.
[0010] More specifically, the object of the present invention is to
provide an agent for diagnosing cancer that specifically emits
fluorescence in a cancerous tissue when applied to a part in which
presence of a cancerous tissue is suspected, and also to provide an
agent for diagnosing cancer that can achieve prompt identification
of a cancerous tissue in a surgical operation, endoscopy, or the
like.
Means for Achieving the Object
[0011] The inventors of the present invention conducted various
researches to achieve the aforementioned object. As a result, they
found that when a compound represented by the following general
formula (I), which acts as a fluorescent probe for measurement of
.gamma.-glutamyltransferase, was applied to a part in which
presence of a cancerous tissue is suspected, intense fluorescence
was specifically emitted only from the cancerous tissue, and
intensity of the fluorescence reached to a sufficient level within
a shot time, e.g. approximately within several tens of seconds to
several minutes, to successfully achieve extremely easy
identification of the cancerous tissue. The present invention was
accomplished on the basis of the aforementioned findings.
[0012] The present invention thus provides an agent for diagnosing
cancer comprising a compound represented by the following general
formula (I);
##STR00002##
wherein R.sup.1 represents hydrogen atom, or the same or different
one to four substituents binding to the benzene ring; R.sup.2,
R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 independently
represent hydrogen atom, hydroxyl group, an alkyl group, or a
halogen atom; R.sup.8 and R.sup.9 independently represent hydrogen
atom, or an alkyl group; and X represents a C.sub.1-C.sub.3
alkylene group, or a salt thereof as an active ingredient.
[0013] According a preferred embodiment of the aforementioned
invention, there is provided the aforementioned agent for
diagnosing cancer comprising the aforementioned compound or a salt
thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are hydrogen atoms, and X is
methylene group.
[0014] According to other preferred embodiments of the present
invention, there are provided the aforementioned agent for
diagnosing cancer, which is used for a surgical treatment of a
cancer or a diagnosis for a cancer; the aforementioned agent for
diagnosing cancer, wherein the surgical treatment of a cancer or
the diagnosis for a cancer is an open surgery such as craniotomy,
thoracotomy or laparotomy, an endoscopic surgery, or endoscopy; and
the aforementioned agent for diagnosing cancer, which is used for
quick diagnosis during surgery.
[0015] The present invention also provides use of a compound
represented by the aforementioned general formula (I) or a salt
thereof for manufacture of the aforementioned agent for diagnosing
cancer.
[0016] From another aspect of the present invention, there is
provided a method for diagnosing a cancer, which comprises the
following steps:
(1) the step of applying a compound represented by the
aforementioned general formula (I) or a salt thereof to a part of a
living body containing a cancerous tissue, and (2) the step of
identifying the cancerous tissue in the part of a living body by
detecting fluorescence emitted by a compound represented by the
following general formula (II):
##STR00003##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6,
R.sup.7, R.sup.8, R.sup.9, and X have the same meanings as those
defined above) or a salt thereof which is generated in the
cancerous tissue.
EFFECT OF THE INVENTION
[0017] By using the agent for diagnosing cancer provided by the
present invention, intense fluorescence is specifically emitted
only from a cancerous tissue, and accordingly, it becomes possible
to accurately identify a cancerous tissue. Further, the agent for
diagnosing cancer of the present invention gives extremely intense
fluorescence in a cancerous tissue within a short time of from
about several tens of seconds to several minutes, the agent has a
characteristic feature in that extremely quick identification of a
cancerous tissue during a surgical operation or a diagnosis is
achieved. Furthermore, the agent also has a characteristic feature
in that diagnosis using the agent for diagnosing cancer of the
present invention can be carried out by means of a visible light
which is safe for living bodies.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] FIG. 1 This figure shows changes of absorption and
fluorescence spectrum of Compound (2) (.gamma.Glu-RhoHM) after the
reaction with .gamma.-glutamyltranspeptidase (GGT), and the
reaction quantifiability of .gamma.Glu-RhoHM.
[0019] FIG. 2 This figure shows an image obtained by imaging using
Compound (2) from the outside of the body.
[0020] FIG. 3 This figure shows an intraabdominal image after
laparotomy (upside) and mesenteric image after laparotomy
(downside) obtained by imaging using Compound (2). In each image, a
white light image is shown on the left side, and a fluorescence
image is shown on the right side.
[0021] FIG. 4 This figure shows images obtained by live imaging
using a fluorescence endoscope with Compound (2). In each of the
results obtained immediately after spray (0 sec), and 30 seconds,
60 seconds, 90 seconds, and 10 minutes after the spray, a white
light image is shown on the left side, and a fluorescence image is
shown on the right side. The "white light image" is an image
obtained in a usual endoscope mode, not a fluorescence mode, for
comparison.
MODES FOR CARRYING OUT THE INVENTION
[0022] The alkyl group mentioned in this specification may be a
linear, branched or cyclic alkyl group, or may be an alkyl group
consisting of a combination thereof. Although the carbon number of
the alkyl group is not particularly limited, the number may be, for
example, about 1 to 6, preferably about 1 to 4. The alkyl group
mentioned in this specification may have one or more arbitrary
substituents. Examples of the substituent include, for example, an
alkoxyl group, a halogen atom (the halogen atom may be any of
fluorine atom, chlorine atom, bromine atom, and iodine atom), amino
group, a mono- or di-substituted amino group, a substituted silyl
group, an acyl group, and the like, but the substituent is not
limited to these examples. When the alkyl group has two or more
substituents, they may be the same or different. The above
descriptions are similarly applied to alkyl moieties of other
substituents containing an alkyl moiety (for example, an alkyloxy
group, an aralkyl group, and the like).
[0023] The aryl group mentioned in this specification may be either
a monocyclic aryl group or a condensed polycyclic aryl group, and
may contain one or more heteroatoms (for example, oxygen atom,
nitrogen atom, sulfur atom and the like) as ring-constituting
atoms. The aryl group mentioned in this specification may have one
or more arbitrary substituents on the ring. Examples of the
substituent include, for example, an alkoxyl group, a halogen atom,
amino group, a mono- or di-substituted amino group, a substituted
silyl group, an acyl group, and the like, but the substituent is
not limited to these examples. When the aryl group has two or more
substituents, they may be the same or different. The above
descriptions are similarly applied to aryl moieties of other
substituents containing an aryl moiety (for example, an aryloxy
group, an aralkyl group, and the like).
[0024] R.sup.1 represents hydrogen atom, or one to four
substituents binding to the benzene ring. Examples of the
substituent include, for example, an alkyl group, an alkoxyl group,
a halogen atom, amino group, a mono- or di-substituted amino group,
a substituted silyl group, an acyl group, and the like, but the
substituent is not limited to these examples. When there are two or
more substituents on the benzene ring, they may be the same or
different. As R.sup.1, hydrogen atom is preferred.
[0025] R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7
independently represent hydrogen atom, hydroxyl group, an alkyl
group, or a halogen atom. It is preferred that R.sup.2 and R.sup.7
are hydrogen atoms. It is also preferred that R.sup.3, R.sup.4,
R.sup.5 and R.sup.6 are hydrogen atoms. It is more preferred that
all of R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are
hydrogen atoms.
[0026] R.sup.8 and RD independently represent hydrogen atom or an
alkyl group. When both R.sup.8 and R.sup.6 represent an alkyl
group, they may be the same or different. For example, it is
preferred that both R.sup.8 and R.sup.9 are hydrogen atoms, or
R.sup.8 is an alkyl group and R.sup.9 is hydrogen atom, and it is
more preferred that both R.sup.8 and R.sup.9 are hydrogen
atoms.
[0027] X represents a C.sub.1-C.sub.3 alkylene group. The alkylene
groups may be either a linear alkylene group or a branched alkylene
group. For example, in addition to methylene group (--CH.sub.2--),
ethylene group (--CH.sub.2--CH.sub.2--), and propylene group
(--CH.sub.2--CH.sub.2--CH.sub.2--), --CH(CH.sub.3)--,
--CH.sub.2--CH(CH.sub.3)--, --CH(CH.sub.2CH.sub.3)--, and the like
can also be used as branched alkylene groups. Among them, methylene
group and ethylene group are preferred, and methylene group is more
preferred.
[0028] The compound represented by the aforementioned general
formula (I) may exist as a salt. Examples of the salt include a
base addition salt, an acid addition salt, an amino acid salt, and
the like. Examples of the base addition salt include, for example,
metal salts such as sodium salts, potassium salts, calcium salts,
and magnesium salts; ammonium salts, and organic amine salts such
as triethylamine salts, piperidine salts, and morpholine salts.
Examples of the acid addition salt include, for example, mineral
acid salts such as hydrochlorides, sulfates, and nitrates, and
organic acid salts such as methanesulfonates, p-toluenesulfonates,
citrates, and oxalates. Examples of the amino acid salt include
glycine salts and the like. However, salts of the compounds of the
present invention are not limited to these examples.
[0029] The compound represented by the general formula (I) may have
one or two or more asymmetric carbons depending on the type of the
substituent, and stereoisomers such as optical isomers or
diastereoisomers may exist. Such stereoisomers in pure forms,
arbitrary mixtures of stereoisomers, racemates and the like all
fall within the scope of the present invention.
[0030] The compound represented by the general formula (I) or a
salt thereof may exist as a hydrate or a solvate, and any of these
substances fall within the scope of the present invention. The type
of solvent that forms the solvate is not particularly limited. For
example, such solvents as ethanol, acetone and isopropanol can be
exemplified.
[0031] The compound of represented by the general formula (I) can
be readily prepared from, for example, a xanthene compound having
amino groups at the 3- and 6-positions and 2-carboxyphenyl group or
a 2-alkoxycarbonylphenyl group at the 9-position or the like used
as the starting material by, for example, converting the
2-carboxyphenyl group or 2-alkoxycarbonylphenyl group at the
9-position into a hydroxyalkyl group and then acylating the amino
group at the 3-position. As the 3,6-diaminoxanthene compound usable
as the starting material, examples include, for example, rhodamine
110, rhodamine 123 and the like, which are all commercially
available, but the 3,6-diaminoxanthene compound is not limited to
these examples, and an appropriate xanthene compound can be chosen
depending on the structure of the objective compound.
[0032] A preparation method for a typical compound among the
compounds of the present invention represented by the general
formula (I) is specifically described in the examples mentioned in
this specification, and accordingly, those skilled in the art can
readily prepare an arbitrary compound among the compounds
represented by the general formula (I), by referring to the
disclosures of the present specification, and appropriately
choosing starting materials, reagents, reaction conditions, and the
like, as required.
[0033] The compound represented by the general formula (I) per se
is substantially non-fluorescent. Whilst, when the .gamma.-glutamyl
group is hydrolyzed by .gamma.-glutamyltransferase, the compound
promptly becomes a tautomer having an open ring structure to give a
strongly fluorescent compound represented by the general formula
(II). Therefore, the agent for diagnosing cancer of the present
invention comprising the compound represented by the general
formula (I) or a salt thereof as an active ingredient has a
property that the agent is hydrolyzed by
.gamma.-glutamyltransferase specifically and strongly expressed in
a cancerous tissue to give a compound represented by general
formula (II) that emits intense fluorescence in the cancerous
tissue, and by applying the agent to a part in which presence of a
cancerous tissue is suspected, only a cancerous tissue comes to
specifically emit intense fluorescence within several tens of
seconds to several minutes.
[0034] For example, when the compound represented by the general
formula (I) or a salt thereof is irradiated with an excitation
light of about 440 to 500 nm in a neutral pH region, the compound
emits almost no fluorescence, whilst the compound represented by
the general formula (II) has a property of emitting strong
fluorescence under the same conditions (for example, emission: 524
nm). Therefore, when diagnosis is carried out by using the agent
for diagnosing cancer of the present invention, usually a visible
light of about 440 to 500 nm, preferably a visible light of about
445 to 490 nm, more preferably a visible light of about 450 to 480
nm, can be irradiated. The wavelength of fluorescence to be
observed is usually about 510 to 800 nm, and for example, it is
preferable to observe fluorescence of about 516 to 556 nm.
[0035] In this specification, the term "cancerous tissue" means an
arbitrary tissue containing a cancer cell. The term "tissue" should
be construed in its broadest sense, including a part and whole of
organs, and it should not be construed in any limitative way. The
agent for diagnosing cancer of the present invention has an action
of detecting .gamma.-glutamyltransferase specifically and strongly
expressed in a cancerous tissue, and accordingly, the cancerous
tissue is preferably a tissue highly expressing
.gamma.-glutamyltransferase. Such cancerous tissue is explained in,
for example, Biochemical Pharmacology, 71, pp. 231-238, 2006.
Further, in this specification, the term "diagnosis" should be
construed in its broadest sense, including macroscopically or
microscopically confirming presence of a cancerous tissue in an
arbitrary part of a living body.
[0036] The agent for diagnosing cancer of the present invention can
be used, for example, during a surgical operation or a diagnosis.
In this specification, the term "surgical operation" encompasses
arbitrary surgeries applied for cancer therapy including open
surgeries such as craniotomy, thoracotomy and laparotomy, skin
operations, and the like, which are accompanied by incision, as
well as endoscopic surgeries using gastroscope, large intestine
endoscope, laparoscope, thoracoscope, or the like. The term
"diagnosis" encompasses diagnostic treatments using an endoscope
such as gastroscope and large intestine endoscope, procedures
accompanying diagnostic treatments such as excision and collection
of tissues, as well as diagnostic treatments performed for tissues
extracted and collected from living bodies, and the like. These
terms should be construed in their broadest senses, and they should
not be construed in any limitative way.
[0037] Cancers that can be diagnosed with the agent for diagnosing
cancer of the present invention are not particularly limited, and
encompass arbitrary malignant tumors including sarcoma. The agent
is preferably used for diagnosis of a solid carcinoma. As one of
preferred embodiments, for example, the agent for diagnosing cancer
of the present invention can be applied to a part or whole of a
field of surgical operation performed macroscopically or under an
endoscope by an appropriate method such as spray, application, or
infusion, and after several tens of seconds to several minutes, the
part applied can be irradiated with a light of a wavelength of
about 500 nm. When a cancerous tissue is included in the part
applied, the tissue comes to emit fluorescence, and therefore the
tissue is identified as a cancerous tissue, and is excised together
with surrounding tissues. For example, in surgical treatments of
typical carcinomas such as gastric cancer, lung cancer, breast
cancer, colon cancer, liver cancer, gall bladder cancer, and
pancreatic cancer, definite diagnosis can be performed for
carcinoma tissues that can be macroscopically confirmed, and
infiltration, metastasis and the like into lymphoid tissues such as
lymph nodes, as well as circumferential organs and tissues can also
be diagnosed. Therefore, it becomes possible to perform quick
diagnosis during a surgery to determine a region to be excised.
[0038] As another preferred embodiment, for example, in gastroscopy
or large intestine endoscopy, the agent for diagnosing cancer of
the present invention can be applied to a part to be tested by an
appropriate method such as spray, application, or infusion, and
after several tens of seconds to several minutes, the part applied
can be irradiated with a light of a wavelength of about 500 nm, and
when a tissue emitting fluorescence is detected, the tissue can be
identified as a cancerous tissue. When a cancerous tissue is
identified in endoscopy, diagnostic or therapeutic resection can be
performed against the tissue.
[0039] A concentration for application of the agent for diagnosing
cancer of the present invention is not particularly limited. The
agent can be preferably applied to a tissue, in which presence of a
cancerous tissue is suspected, as a solution of a concentration of
about 1 to 1,000 .mu.M, and the agent is generally preferably
applied under a neutral condition. The agent can be used in the
range of, for example, pH 5.0 to 9.0, preferably pH 6.0 to 8.0,
more preferably pH 6.8 to 7.6. Although the compound represented by
the aforementioned general formula (I) or a salt thereof, per se,
may be used as the agent for diagnosing cancer of the present
invention, the compound or a salt thereof may be used as a
composition by mixing the compound or a salt thereof with additives
generally used for preparation of reagents, if necessary. For
example, as additives for use of reagents under a physiological
condition, such additives as dissolving aids, pH adjusters,
buffers, and isotonic agents can be used, and amounts of these
additives can suitably be chosen by those skilled in the art. Such
a composition may be provided as those in appropriate forms, for
example, powdery mixtures, lyophilized products, granules, tablets,
solutions and the like, and they can be dissolved in water for
injection or an appropriate buffer at the time of use, and
applied.
EXAMPLES
[0040] The present invention will be more specifically explained
with reference to examples. However, the scope of the present
invention is not limited to the following examples.
Example 1
[0041] Compound (2) was prepared according to the following
scheme.
##STR00004##
(a) Synthesis of Compound (1)
RhoHM
[0042] Rhodamine 110 (285 mg, 0.8 mmol, 1 eq.) was dissolved in
methanol (10 mL), the solution was added with sulfuric acid, and
the mixture was stirred at 80.degree. C. for 10 hours under an
argon atmosphere. The reaction solvent was removed under reduced
pressure, and the residue was washed with saturated aqueous sodium
hydrogencarbonate and water. The resulting solid was dissolved in
tetrahydrofuran (THF, 10 mL), the solution was added with a 5 M
sodium methoxide solution (in methanol, 400 .mu.L, 0.8 mmol, 1 eq.)
at 0.degree. C. under an argon atmosphere, and the mixture was
stirred for 10 minutes. Then, the mixture was added with lithium
aluminum hydride (333 mg, 8 mmol, 10 eq.), and the mixture was
stirred for 3 hours. The reaction mixture was added with saturated
aqueous ammonium chloride (5 mL), the solvent was removed under
reduced pressure, and the resulting solid was extracted with
dichloromethane and a saturated aqueous solution of tartaric acid
tetrahydrate potassium and sodium salt. The organic layer was added
with sodium sulfate, and filtered, and then the solvent was removed
to obtain a solid. The resulting solid was dissolved in
dichloromethane, the solution was added with chloranil (196 mg, 1
mmol, 1 eq.), and the mixture was stirred at room temperature for
30 minutes. The solvent was removed under reduced pressure, and the
residue was purified by silica gel chromatography
(dichloromethane/methanol=10:1) to obtain the objective compound
(104 mg, 41%).
[0043] .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 7.64 (d, 111,
J=7.7 Hz), 7.56 (t, 1H, J=7.6 Hz), 7.44 (t, 1H, J=7.5 Hz), 7.17 (d,
1H, J=7.5 Hz), 7.03-7.00 (m, 2H), 6.71-6.74 (m, 4H), 4.23 (s,
2H)
[0044] .sup.13C NMR (400 MHz, CD.sub.3-OD): .delta. 161.5, 159.9,
159.6, 141.0, 133.4, 132.2, 131.3, 130.3, 129.5, 128.8, 118.0,
115.0, 98.4, 62.8
[0045] HRMS (ESI+) Calcd for [M+H]+, 317.12900. Found, 317.12862
(-0.38 mmu)
(b) Synthesis of Compound (2)
.gamma.Glu-RhoHM
[0046] Compound (1) (0.05 mmol, 1 eq.), HATU (0.11 mmol, 2 eq.) and
N,N-diisopropylethylamine (0.11 mmol, 2 eq.) were dissolved in
dimethylformamide (DMF, 2 mL), and the solution was stirred at
0.degree. C. for 10 minutes under an argon atmosphere. Then, DMF
(0.5 mL) dissolving Boc-Glu-OtBu (0.05 mmol, 1 eq.) was added to
the solution, and the mixture was stirred for 15 hours. The
reaction solvent was removed under reduced pressure, then the
obtained solid was dissolved in dichloromethane (2 mL) and
trifluoroacetic acid (TFA, 2 mL), and the solution was stirred for
30 minutes. The solvent was removed, and the residue was purified
by using HPLC (Eluent A:H.sub.2O containing 0.1% TFA, Eluent B:
CH.sub.3CN (80%) and 1120 (20%) containing 0.1% TFA, A/B=80/20 to
0/100 over 40 minutes) to obtain the objective compound.
Compound (2)
[0047] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.39 (s, 1H),
7.62-7.61 (m, 2H), 7.50-7.47 (m, 1H), 7.39 (d, 1H, J=7.8 Hz),
7.24-7.22 (m, 3H), 6.94 (d, 1H, J=8.3 Hz), 6.86 (s, 1H), 4.25 (s,
2H), 3.96 (t, 1H, J=6.3 Hz), 2.71-2.69 (m, 2H), 2.30-2.27 (m,
2H)
[0048] .sup.13C NMR (400 MHz, CD.sub.3OD): .delta.173.4, 171.8,
164.5, 163.1, 160.7, 157.1, 148.7, 141.2, 134.9, 131.9, 131.7,
130.5, 129.8, 129.0, 121.4, 119.4, 118.5, 106.9, 98.5, 63.1, 53.5,
33.4, 26.6
[0049] HRMS (ESI+) Calcd for [M+H]+, 446.17160. Found, 446.17195
(+0.36 mmu).
Example 2
[0050] Compound (2) (.gamma.Glu-RhoHM) formed by binding the acyl
residue derived from glutamic acid to one amino group of Compound
(1) (RhoHM) was dissolved in a neutral phosphate buffer, and
.gamma.-glutamyltranspeptidase (GGT, equine kidney, SIGMA
G9270-100UN) was reacted with the solution. Specifically, 3 .mu.L
of a 5 .mu.M solution of the compound in dimethyl sulfoxide (DMSO)
was dissolved at a final concentration of 5 in 3 mL of a 0.1 M
sodium phosphate buffer (pH 7.4), and GGT (1.1 U) was added for the
enzymatic reaction at 37.degree. C. The excitation wavelength was
501 nm. As a result, a compound having an open ring structure was
produced by hydrolysis of the acyl group, and remarkable elevations
of absorption and fluorescence intensity were immediately observed
(FIG. 1).
[0051] The DMSO solution of the compound (5 inn in a volume of 3
.mu.L was dissolved in 3 mL of a 0.1 M sodium phosphate buffer (pH
7.4) at a final concentration of 5 .mu.M, and the enzymatic
reaction was performed at 37.degree. C. The values of fluorescence
intensity observed with each amount of the enzyme 9 minutes after
the addition of the enzyme were plotted. The excitation wavelength
was 501 nm, and the fluorescence emission wavelength was 524 nm. As
a result, the compound gave linear increase of fluorescence
intensity in an added GGT amount-dependent manner (FIG. 1).
Example 3
[0052] Enzyme specificity of Compound (2) was examined. The DMSO
solution (5 mM) in a volume of 3 .mu.L was dissolved in 3 mL of a
0.1 M sodium phosphate buffer (pH 7.4) at a final concentration of
5 .mu.M, and LAP (0.4 U) was added to the solution to perform the
enzymatic reaction at 37.degree. C. As a result, increase of
fluorescence intensity was not observed after the reaction of
Compound (2) (.gamma.Glu-RhoHM) with LAP. Whilst, Compound (2)
reacted with GGT to give remarkable fluorescence intensity (Example
2), and therefore it was considered that .gamma.Glu-RhoHM
specifically detected GGT.
Example 4
Fluorescence Imaging Using Cancer Model Mouse
[0053] Disseminated metastasis of ovarian cancer to the peritoneum
is known as a generally-occurring lethal complication of ovarian
cancer. Such metastasis to the peritoneum begins to occur at a
relatively early stage of ovarian cancer, the tumor invades the
chorionic membrane, and falls into the abdominal cavity, and as a
result, the tumor metastasizes to the other organs in the abdominal
cavity as seeds are scattered (dissemination metastasis). In order
to experimentally reproduce this phenomenon, SHIN3 cells of ovarian
cancer origin were intraperitoneally administered to athymic mice
to prepare a peritoneal dissemination model (Neoplasia, 8, pp.
607-612, 2006).
[0054] The SHIN3 cells derived from human ovarian cancer were
cultured at 37.degree. C. in the RPMI 1640 medium containing 10%
FBS, 100 U/mL of penicillin, and 100 .mu.g/mL of streptomycin under
5% CO.sub.2. After the cells reached subconfluent, the cells were
washed with PBS (phosphate buffered saline), and removed with
Trypsin-EDTA so that individual cells were separated. The treated
cells were centrifuged (100.times.g, 4.degree. C., 3 minutes), and
after the supernatant was discarded, ice-cooled PBS was added to
the cells to suspend them at a cell density of 1.times.10.sup.6
cells/300 .mu.L. The prepared cell suspension was immediately
intraperitoneally administered to about 8-week old athymic mice in
a volume of 300 .mu.L (1.times.10.sup.6 cells) per mouse. The
treated mice were bred for about 5 to 10 days. Formation of a large
number of tumors of about 0.1 mm to several millimeters on sites
adjacent to the pancreas and spleen and on the mesenterium was
confirmed generally in this period.
[0055] A solution of Compound (2) (.gamma.Glu-RhoHM) in PBS (50
.mu.M) in a volume of 300 .mu.L was intraperitoneally (i.p.)
administered to the peritoneal dissemination model mice.
Fluorescence imaging was performed by irradiating an excitation
light of 450 to 480 nm from the outside of the mouse body under
anesthesia 30 minutes after the i.p. administration, and observing
fluorescence of 516 to 556 nm. Further, after the mice were
sacrificed with CO.sub.2 gas, and exsanguination was performed,
abdominal section was performed with surgery appliances for small
animals to expose the abdominal cavity, an excitation light of 445
to 490 nm was irradiated, and fluorescence was measured at every 10
nm from 520 to 800 nm to obtain fluorescence spectrum images.
[0056] As a result, strong green fluorescence was observed in a
cancer site-specific manner. An image obtained by the imaging
performed from the outside of bodies before the abdominal section
are shown in FIG. 2 (30 minutes after the administration of
Compound (2)). In FIG. 3, the upper image is obtained by
intraperitoneal imaging performed after the abdominal section (30
minutes after the administration of Compound (2)), and the lower
image is obtained by mesentery imaging performed after the
abdominal section (30 minutes after the administration of Compound
(2)). In each image, a white light image is shown on the left side,
and a fluorescence image is shown on the right side.
Example 5
Live Imaging of Cancer Model Mouse Using Fluorescent Endoscope
[0057] A small hole was formed in the abdominal part of the
peritoneal dissemination model mouse under isoflurane anesthesia, a
fluorescence endoscope was inserted into the abdominal cavity
through the hole, and 300 .mu.L of a solution of Compound (2)
(.gamma.Glu-RhoHM) in PBS (50 .mu.M) was sprayed in a misty state
from the tip of the endoscope. Then, an excitation light of 450 to
480 nm was irradiated, and fluorescence of 516 to 556 nm was
observed over time to obtain fluorescence endoscope movies and
images. The results are shown in FIG. 4. In each of the results
obtained immediately after the spray (0 sec), and 30 seconds, 60
seconds, 90 seconds, and 10 minutes after the spray, a white light
image is shown on the left side, and a fluorescence image is shown
on the right side. The "white light image" is an image obtained in
a usual endoscope mode, not a fluorescence mode for comparison. It
can be confirmed that the cancerous tissue images became clearer in
the fluorescence images from immediately after the spray to 90
second thereafter. Further, even after 10 minutes, the cancerous
tissues were clearly imaged (similarly, the "white light image" is
an image obtained in a usual endoscope mode for comparison, not in
a fluorescence mode). As a result, it was observed that a cancerous
part was made to specifically emit fluorescence within several
minutes by using the agent for diagnosing cancer of the present
invention.
* * * * *